165 related articles for article (PubMed ID: 37880179)
1. Glucocorticoid trajectories over 2 years in patients with rheumatoid arthritis in a real-life setting.
Delteil A; Lambert C; Pereira B; Couderc M; Malochet-Guinamand S; Pickering ME; Villedon M; Mathieu S; Soubrier M; Tournadre A
RMD Open; 2023 Oct; 9(4):. PubMed ID: 37880179
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of low-dose glucocorticoids combined with methotrexate and hydroxychloroquine in the treatment of early rheumatoid arthritis: A single-center, randomized, double-blind clinical trial.
Hua L; Du H; Ying M; Wu H; Fan J; Shi X
Medicine (Baltimore); 2020 Jul; 99(27):e20824. PubMed ID: 32629668
[TBL] [Abstract][Full Text] [Related]
3. Comparative effectiveness of treatment with the first TNF antagonist in monotherapy, the first TNF antagonist plus one conventional synthetic disease-modifying antirheumatic drug, and the first TNF antagonist plus two or more conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis.
Hernández-Cruz B; Márquez-Saavedra E; Caliz-Caliz R; Navarro-Sarabia F
Arthritis Res Ther; 2016 Nov; 18(1):259. PubMed ID: 27821150
[TBL] [Abstract][Full Text] [Related]
4. Does addition of glucocorticoids to the initial therapy influence the later course of the disease in patients with early RA? Results from the Swiss prospective observational registry (SCQM).
Mueller RB; Reshiti N; Kaegi T; Finckh A; Haile SR; Schulze-Koops H; Schiff M; Spaeth M; von Kempis J;
Clin Rheumatol; 2017 Jan; 36(1):59-66. PubMed ID: 27838788
[TBL] [Abstract][Full Text] [Related]
5. Glucocorticoid use in rheumatoid arthritis patients and the onset of pneumonia: a systematic review and meta-analysis.
Elsouri KN; Arboleda V; Basbous L; Heiser S; Collins DP; Ragusa P; Baxter C; Cabrera D; Akhand T; Stermer E; Sharma K; Seguro C; Hardigan P; Kesselman M; Beckler MD
J Osteopath Med; 2023 Apr; 123(4):179-186. PubMed ID: 36691851
[TBL] [Abstract][Full Text] [Related]
6. Dynamical trajectory of glucocorticoids tapering and discontinuation in patients with rheumatoid arthritis commencing glucocorticoids with csDMARDs: a real-world data from 2009 to 2020.
Xie W; Huang H; Li G; Hao Y; Gui Y; Wang Y; Deng X; Zhao J; Geng Y; Ji L; Zhang X; Song Z; Zhang Z
Ann Rheum Dis; 2021 Aug; 80(8):997-1003. PubMed ID: 33811037
[TBL] [Abstract][Full Text] [Related]
7. Efficacy, duration of use and safety of glucocorticoids: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis.
Bergstra SA; Sepriano A; Kerschbaumer A; van der Heijde D; Caporali R; Edwards CJ; Verschueren P; de Souza S; Pope JE; Takeuchi T; Hyrich KL; Winthrop KL; Aletaha D; Stamm TA; Schoones JW; Smolen JS; Landewé RBM
Ann Rheum Dis; 2023 Jan; 82(1):81-94. PubMed ID: 36410794
[TBL] [Abstract][Full Text] [Related]
8. Prediction of flare following glucocorticoids withdrawal in rheumatoid arthritis patients with continuation of csDMARDs: a real-life study.
Xie W; Huang H; Zhang Z
Intern Emerg Med; 2023 Sep; 18(6):1759-1767. PubMed ID: 37418144
[TBL] [Abstract][Full Text] [Related]
9. Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16 weeks of treatment: the CareRA trial.
Verschueren P; De Cock D; Corluy L; Joos R; Langenaken C; Taelman V; Raeman F; Ravelingien I; Vandevyvere K; Lenaerts J; Geens E; Geusens P; Vanhoof J; Durnez A; Remans J; Vander Cruyssen B; Van Essche E; Sileghem A; De Brabanter G; Joly J; Meyfroidt S; Van der Elst K; Westhovens R
Ann Rheum Dis; 2015 Jan; 74(1):27-34. PubMed ID: 25359382
[TBL] [Abstract][Full Text] [Related]
10. [Reduction in the need for glucocorticoids on the background of therapy with biologic disease-modifying antirheumatic drugs and Janus kinase inhibitors in rheumatoid arthritis: evidence from real clinical practice].
Potapova AS; Karateev AE; Polishchuk EY; Filatova ES; Amirdzhanova VN; Lila AM
Ter Arkh; 2024 Jun; 96(5):465-470. PubMed ID: 38829807
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of methotrexate with step-down glucocorticoid remission induction (COBRA Slim) versus other intensive treatment strategies for early rheumatoid arthritis in a treat-to-target approach: 1-year results of CareRA, a randomised pragmatic open-label superiority trial.
Verschueren P; De Cock D; Corluy L; Joos R; Langenaken C; Taelman V; Raeman F; Ravelingien I; Vandevyvere K; Lenaerts J; Geens E; Geusens P; Vanhoof J; Durnez A; Remans J; Vander Cruyssen B; Van Essche E; Sileghem A; De Brabanter G; Joly J; Meyfroidt S; Van der Elst K; Westhovens R
Ann Rheum Dis; 2017 Mar; 76(3):511-520. PubMed ID: 27432356
[TBL] [Abstract][Full Text] [Related]
12. Meta-Regression of a Dose-Response Relationship of Methotrexate in Mono- and Combination Therapy in Disease-Modifying Antirheumatic Drug-Naive Early Rheumatoid Arthritis Patients.
Bergstra SA; Allaart CF; Stijnen T; Landewé RBM
Arthritis Care Res (Hoboken); 2017 Oct; 69(10):1473-1483. PubMed ID: 27992656
[TBL] [Abstract][Full Text] [Related]
13. Randomised comparison of initial triple DMARD therapy with methotrexate monotherapy in combination with low-dose glucocorticoid bridging therapy; 1-year data of the tREACH trial.
de Jong PH; Hazes JM; Han HK; Huisman M; van Zeben D; van der Lubbe PA; Gerards AH; van Schaeybroeck B; de Sonnaville PB; van Krugten MV; Luime JJ; Weel AE
Ann Rheum Dis; 2014 Jul; 73(7):1331-9. PubMed ID: 24788619
[TBL] [Abstract][Full Text] [Related]
14. Five-year treat-to-target outcomes after methotrexate induction therapy with or without other csDMARDs and temporary glucocorticoids for rheumatoid arthritis in the CareRA trial.
Stouten V; Westhovens R; Pazmino S; De Cock D; Van der Elst K; Joly J; Bertrand D; Verschueren P
Ann Rheum Dis; 2021 Aug; 80(8):965-973. PubMed ID: 33811036
[TBL] [Abstract][Full Text] [Related]
15. Low-dose prednisolone in rheumatoid arthritis: adverse effects of various disease modifying antirheumatic drugs.
Malysheva OA; Wahle M; Wagner U; Pierer M; Arnold S; Häntzschel H; Baerwald CG
J Rheumatol; 2008 Jun; 35(6):979-85. PubMed ID: 18412314
[TBL] [Abstract][Full Text] [Related]
16. In the era of disease-modifying antirheumatic drugs, how close are we to treating rheumatoid arthritis without the use of glucocorticoids?
Yagiz B; Coskun BN; Pehlivan Y; Dalkilic E; Kiraz S; Yazisiz V; Kucuksahin O; Erden A; Kanitez NA; Kimyon G; Emmungil H; Bilge SY; Kasifoglu T; Bes C; Bolek EC; Bilgin E; Karatas A; Kelesoglu B; Ersozlu D; Gonullu EO; Mercan R; Yilmaz S; Karadag O; Akar S; Ertenli I; Kalyoncu U
Rheumatol Int; 2021 Nov; 41(11):1915-1924. PubMed ID: 34226947
[TBL] [Abstract][Full Text] [Related]
17. Prevalence and risk factors associated with vertebral osteoporotic fractures in patients with rheumatoid arthritis.
Tong JJ; Xu SQ; Zong HX; Pan MJ; Teng YZ; Xu JH
Clin Rheumatol; 2020 Feb; 39(2):357-364. PubMed ID: 31691041
[TBL] [Abstract][Full Text] [Related]
18. [Long-term use of glucocorticoids in patients with active rheumatoid arthritis: therapeutic "freeze frame"].
Gordeev AV; Matyanova EV; Galushko EA
Ter Arkh; 2023 Jul; 95(5):380-385. PubMed ID: 38158989
[TBL] [Abstract][Full Text] [Related]
19. Tapering and discontinuation of oral glucocorticoids without deterioration of disease status in patients with rheumatoid arthritis under a stable treatment.
Hirata S; Kohno H; Watanabe H; Tokunaga T; Yoshida Y; Sugimoto T; Mokuda S; Oda K; Nojima T; Sugiyama E
Mod Rheumatol; 2021 Jul; 31(4):803-808. PubMed ID: 33325280
[TBL] [Abstract][Full Text] [Related]
20. Effect of Glucocorticoids on the Clinical and Radiographic Efficacy of Tofacitinib in Patients with Rheumatoid Arthritis: A Posthoc Analysis of Data from 6 Phase III Studies.
Charles-Schoeman C; van der Heijde D; Burmester GR; Nash P; Zerbini CAF; Connell CA; Fan H; Kwok K; Bananis E; Fleischmann R
J Rheumatol; 2018 Feb; 45(2):177-187. PubMed ID: 29142036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
